Synergistic inhibition of stemness‐related pathways including Wnt, TGF‐β, and Hedgehog signaling may improve the efficacy of ICB treatment targeting CD200 or CD276 in breast cancer stem cells. The gene discussed is CD276; the disease is breast carcinoma.